Avanir Pharmaceuticals, Inc. (Nasdaq:AVNR) announced that data from its CNS therapeutics franchise, specifically in its pseudobulbar affect (PBA) and migraine development programs will be presented at the 66th American Academy of Neurology (AAN) Annual Meeting in Philadelphia. In addition, an article in the peer-reviewed publication, US Neurology, discussing PBA diagnosis in patients with Alzheimer’s disease (AD) and other dementias, will be available at AAN and was recently published online. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) shares after opening at $3.27 moved to $3.46 on last trade day and at the end of the day closed at $3.18. Company price to sales ratio in past twelve months was calculated as 5.66 and price to cash ratio as 11.03. Avanir Pharmaceuticals Inc (NASDAQ:AVNR) showed a negative weekly performance of -8.62%.
Evoke Pharma, Inc. EVOK, a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, announced that data from the Company’s Phase 2b clinical trial of EVK-001, a novel intranasal formulation and delivery method of metoclopramide for diabetic female patients with symptoms associated with gastroparesis, was accepted for an oral presentation at Digestive Disease Week 2014 (DDW). DDW will take place May 3-6, 2014 in Chicago, Illinois. Evoke Pharma Inc (NASDAQ:EVOK) shares fell -4.93% in last trading session and ended the day on $9.06. EVOK return on equity ratio is recorded as 45.10% and its return on assets is -35.30%.
Fibrocell Science Inc (NYSEMKT:FCSC) an autologous cell therapy company primarily focused on developing treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, reported financial results for the fourth quarter and full year ended Dec. 31, 2013.Fibrocell Science Inc (NYSEMKT:FCSC) shares moved down -9.11% in last trading session and was closed at $3.49, while trading in range of $3.26-$4.01. Fibrocell Science Inc (NYSEMKT:FCSC) year to date performance is -14.04%.
NephroGenex Inc (NASDAQ:NRX), a pharmaceutical company focused on the development of therapeutics to treat kidney disease, reported financial results for the year ended December 31, 2013, and provided an update on the Company’s progress and plans. NephroGenex Inc (NASDAQ:NRX) weekly performance is -3.19%. On last trading day company shares ended up $6.67. NephroGenex Inc (NASDAQ:NRX) distance from 50-day simple moving average is -26.22%.
Leave a Reply